Gisbert and Calvet 2012 Spain [48]
|
December 2011
|
HP infection PUD/NUD/others
|
Germany, UK, Japan, Italy, Japan, Korea (2)
|
Concomitant therapy: metronidazole + standard triple therapy
|
Standard triple therapy
|
7
|
984
|
90 % vs. 78 %
|
2.36 (1.67–3.34)
|
0
|
Note: Standard triple therapy: (PPI(ome/rabe/lanso) + amoxicillin + clarithromycin)
|
Lv et al. 2015 China [49]
|
April 2014
|
HP infection; PUD/NUD/others; naïve to treatment or had previous treatment
|
China (4), Taiwan (3), Korea, Turkey
|
Quadruple regimens containing both amoxicillin and tetracycline
|
Other quadruple regimens where amoxicillin and tetracycline were not contained together
|
9
|
1453
|
78.1 % vs. 80.5 %
|
0.90 (0.46–1.78)
|
+
|
US, Italy, Turkey, Taiwan, China
|
Triple therapy containing both amoxicillin and tetracycline
|
Other regimens where amoxicillin and tetracycline were not contained together
|
5
|
840
|
68.8 % vs. 66.7 %
|
1.21 (0.64–2.28)
|
Nishizawa et al. 2014 Japan [54]
|
July 2014
|
HP infection
|
Japan (5), Korea
|
Rebamipide containing regimen: rebamipide+
|
Rebamipide NOT-containing regimen: none or mucosal protective agents other than rebamipide (teprenone/plaunotol)+
|
6
|
611
|
63.5 % vs. 52.7 %
|
1.59 (1.14–2.22)
|
+
|
+PPI(lanso/ome) + antibiotics (amoxicillin/metronidazole)
|